(19)
(11)EP 3 582 810 A1

(12)

(43)Date of publication:
25.12.2019 Bulletin 2019/52

(21)Application number: 17879636.3

(22)Date of filing:  05.12.2017
(51)International Patent Classification (IPC): 
A61K 39/395(2006.01)
A61P 35/00(2006.01)
A61K 47/61(2017.01)
(86)International application number:
PCT/US2017/064631
(87)International publication number:
WO 2018/106645 (14.06.2018 Gazette  2018/24)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD TN

(30)Priority: 07.12.2016 US 201662431362 P

(71)Applicant: Innate Biotherapeutics, LLC
Newton, Massachusetts 02459 (US)

(72)Inventors:
  • REZNIK, Gabriel, Oscar
    Bedford, MA 01730 (US)
  • KANE, John, James
    Cambridge, MA 02139 (US)
  • SIEDLECKI, James, Michael
    Burlington, MA 01803 (US)
  • DOSTALOVA, Zuzana
    Cambridge, MA 02141 (US)
  • SANSAL-CASTELLANO, Isabelle
    Jamaica Plain, MA 02130 (US)
  • RUBIN-BEJERANO, Ifat
    Newton, MA 02459 (US)
  • MIAO, Hua
    Newton, MA 02461 (US)
  • FURFINE, Eric Steven
    Lincoln, Massachusetts 01773 (US)

(74)Representative: Snodin, Michael D. 
Park Grove IP BioCity Nottingham Pennyfoot Street
Nottingham NG1 1GF
Nottingham NG1 1GF (GB)

  


(54)ß-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES